Charles River Laboratories International ... The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services ...

Charles River Laboratories International ... The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist ...

Charles River Laboratories International ... The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports.

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

WILMINGTON, Mass., January 13, 2025--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43 rd Annual J.P. Morgan Healthcare ...

Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...